PIK3CA mutations enable targeting of a breast tumor dependency through mTOR-mediated MCL-1 translation.

ABSTRACT: Therapies that efficiently induce apoptosis are likely to be required for durable clinical responses in patients with solid tumors. Using a pharmacological screening approach, we discovered that combined inhibition of B cell lymphoma-extra large (BCL-X_L) and the mammalian target of rapamycin (mTOR)/4E-BP axis results in selective and synergistic induction of apoptosis in cellular and animal models of PIK3CA mutant breast cancers, including triple-negative tumors. Mechanistically, inhibition of mTOR/4E-BP suppresses myeloid cell leukemia-1 (MCL-1) protein translation only in PIK3CA mutant tumors, creating a synthetic dependence on BCL-X_L This dual dependence on BCL-X_L and MCL-1, but not on BCL-2, appears to be a fundamental property of diverse breast cancer

SUBMITTER: Anderson GR 

PROVIDER: S-EPMC5626456 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature